SUZHOU, China, Dec. 3, 2012 /PRNewswire/ -- TOT Biopharm Company Limited has completed the 18-month project constructing the first stage of its US$100 million factory complex in eastern China's Suzhou Industrial Park. The high-tech factory complex specializes in the research and development, production and marketing of anti-cancer drugs globally.
The inauguration ceremony of the new factory complex held on November 23 was attended by celebrities and guests from both mainland China and Taiwan, all of whom witnessed a milestone in the cooperation between the two regions in developing the bio-pharmaceutical sector. Business leaders from both regions, including Wang Shaobang, deputy director of the Taiwan Affairs Office of Jiangsu Province, Yang Zhiping, director of Suzhou Industrial Park, Qianfu, chairman of Cathay United Bank's Culture & Charity Foundation and Gao Konglian, deputy chairman of Straits Exchange Foundation delivered congratulatory speeches at the event, signaling their desire to further the cooperation in the pharmaceutical R&D field between mainland and Taiwan with the new state-of-the-art factory complex. Guests attending the event included leaders in the research and development of anti-cancer drugs from both the mainland and Taiwan, including Sun Yan, academician of the Chinese Academy of Engineering, Jacqueline Whang-Peng, academician of Academia Sinica, Professor Ma Jun, director of the Harbin Institute of Hematology & Oncology and Professor Ann-Lii Cheng, chief of medical oncology at National Taiwan University Hospital.
TOT Biopharm's new factory complex meets the demand for developing the bio-pharmaceutical sector set forth in China's 12th Five-Year Development Planning for Strategic Emerging Industries. The company has leveraged the rapid growth of bio-pharmaceutical technologies in China to accelerate the building of a complete bio-pharmaceutical industry chain. With the support of both the mainland and Taiwan governments, TOT Biopharm chairman Lin Rongjin and general manager Huang Chunying worked closely with their professional teams to create a world leading 50,000-square-meter factory complex for specialty anti-cancer drugs. The company's core products include Liposomal technology-based specialty drugs, biologics and innovative drugs.
The first stage of TOT Biopharm's new factory complex includes an oral anti-cancer drug plant with separate production facilities for both cytotoxics and non-cytotoxics, an injected anti-cancer drug plant and a GMP bio pilot plant with a capacity of 500L cell culture/ purification/ filling. TOT Biopharm is set to initiate the second-stage construction to expand its production scale and improve its international competitiveness, building a position as a pharmaceutical R&D and marketing partner of choice for international bio-pharmaceutical innovators and devoting itself to major cancer treatments in China and to the well-being of people around the world.
SOURCE TOT Biopharm Company Limited